Molecular Partners AG (MOLN) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown
MOLN's revenue distribution by segment and geography
By Geography
MOLN Revenue Analysis (2013–2024)
As of March 2, 2026, Molecular Partners AG (MOLN) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, MOLN's 5-year compound annual growth rate (CAGR) stands at -24.6%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $189.6 million in 2022.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY), MOLN has underperformed the peer group in terms of revenue growth. Compare MOLN vs REGN →
Peer Comparison
Compare MOLN's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MOLNCurrent | $0 | -100.0% | -24.6% | -1231.7% | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $5.0M | -29.4% | $-42,534,000 | -855.8% | $-61,217,000 | -1231.7% |
| 2023 | $7.0M | -96.3% | $-40,806,000 | -579.8% | $-61,108,000 | -868.3% |
| 2022 | $189.6M | +1931.7% | $138.8M | 73.2% | $116.6M | 61.5% |
| 2021 | $9.3M | -0.1% | $-46,388,000 | -497.2% | $-63,418,000 | -679.7% |
| 2020 | $9.3M | -54.2% | $-46,731,000 | -500.1% | $-58,326,000 | -624.2% |
| 2019 | $20.4M | +96.8% | $-23,115,000 | -113.4% | $-36,660,000 | -179.9% |
| 2018 | $10.4M | -48.3% | $-5,247,000 | -50.7% | $-37,410,000 | -361.3% |
| 2017 | $20.0M | -13.1% | $2.2M | 11.0% | $-25,844,000 | -129.1% |
| 2016 | $23.0M | -20.9% | $8.5M | 36.8% | $-19,486,000 | -84.6% |
| 2015 | $29.1M | +9.4% | $28.0M | 96.0% | $-2,218,091 | -7.6% |
See MOLN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MOLN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare MOLN vs AGIO
See how MOLN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is MOLN's revenue growth accelerating or slowing?
MOLN revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of -24.6%. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is MOLN's long-term revenue growth rate?
Molecular Partners AG's 5-year revenue CAGR of -24.6% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is MOLN's revenue distributed by segment?
MOLN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.